Hepatic encephalopathy: Ae NH4 levels and protein restriction obsolete?

Practical Gastroenterology

Volumn 35, Issue 5, 2011, Pages 6-19

  Caruana, Peter ^a   Shah, Neeral ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTIBIOTIC AGENT; BRANCHED CHAIN AMINO ACID; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PLACEBO; RIFAXIMIN;

AMMONIA BLOOD LEVEL; AMMONIA FORMATION; ANTIBIOTIC THERAPY; BRAIN EDEMA; CONSTIPATION; DEHYDRATION; DIAGNOSTIC VALUE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; END STAGE LIVER DISEASE; ENTERIC FEEDING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MALNUTRITION; NAUSEA; NEPHROTOXICITY; NEUROTRANSMISSION; OTOTOXICITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROTEIN RESTRICTION; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; VOMITING;

EID: 80053905011     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
2. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9.
3. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3): 716-721.
4. Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol. 21 2008;14(23):3609-3615.
5. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. Jul 21 2010;16(27):3347-3357.
6. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537-547.
7. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol.2010;7(9):515-525.
8. Mullen KD. The Treatment of Patients With Hepatic Encephalopathy: Review of the Latest Data from EASL 2010. Gastroenterol Hepatol (N Y). 2010;6(7):1-16.
9. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57(8):1156-1165.
10. Krenitsky J. Nutrition for Patients with Hepatic Failure. Practical Gastroenterology. 2003;XXVII(6):23.
11. Krismer F, Roos JC, Schranz M, et al. Saccadic latency in hepatic encephalopathy: a pilot study. Metab Brain Dis. 2010;25(3): 285-295.
12. Nicolao F, Efrati C, Masini A, et al. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol. Apr 2003;38(4):441-446.
13. Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM. 2006;8(6):433-435.
14. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114(3):188-193.
15. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem.2005;38(8):696-699.
16. Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009; 137(3):885-891, 891 e881.
17. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev.2004(2):CD003044.
18. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011; 140(2):478-487 e471.
19. Sidhu SS, Goyal O, Mishra BP, et al. Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial). Am J Gastroenterol. 2011;106(2):307-316.
20. Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med. 1984;76(2):211-222.
21. Kondrup J, Muller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol. 1997;27(1):239-247.
22. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43.
23. Parrish CR, Krenitsky J, McCray S. University of Virginia Health System Nutrition Support Traineeship Syllabus, Charlottesville, VA. Updated 2010.